As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win review voucher
Investors reacted negatively to bluebird bio’s pricing plans for its new sickle cell therapy, as well as the lack of a valuable priority review voucher and black box warning for the treatment.
Friday’s FDA approval of bluebird’s Lyfgenia came two weeks ahead of schedule and on the same day Vertex Pharmaceuticals and CRISPR Therapeutics landed a historic clearance for Casgevy, their CRISPR-based medicine for the same disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.